DK1325011T3 - Fremgangsmåder og forbindelser til behandling af proliferative sygdomme - Google Patents

Fremgangsmåder og forbindelser til behandling af proliferative sygdomme

Info

Publication number
DK1325011T3
DK1325011T3 DK01972948T DK01972948T DK1325011T3 DK 1325011 T3 DK1325011 T3 DK 1325011T3 DK 01972948 T DK01972948 T DK 01972948T DK 01972948 T DK01972948 T DK 01972948T DK 1325011 T3 DK1325011 T3 DK 1325011T3
Authority
DK
Denmark
Prior art keywords
treatment
compounds
methods
proliferative diseases
formula
Prior art date
Application number
DK01972948T
Other languages
Danish (da)
English (en)
Inventor
Kelly Wayne Furness
Sushant Malhotra
David Keyes Clawson
Thomas Albert Engler
Stephen Lyle Briggs
Harold Burns Brooks
Concepcion Sanchez-Martinez
Faming Zhang
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1325011T3 publication Critical patent/DK1325011T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01972948T 2000-09-29 2001-09-24 Fremgangsmåder og forbindelser til behandling af proliferative sygdomme DK1325011T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23661600P 2000-09-29 2000-09-29
PCT/US2001/027728 WO2002028861A2 (en) 2000-09-29 2001-09-24 Methods and compounds for treating proliferative diseases

Publications (1)

Publication Number Publication Date
DK1325011T3 true DK1325011T3 (da) 2004-08-16

Family

ID=22890242

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01972948T DK1325011T3 (da) 2000-09-29 2001-09-24 Fremgangsmåder og forbindelser til behandling af proliferative sygdomme

Country Status (10)

Country Link
US (1) US7109229B2 (de)
EP (1) EP1325011B1 (de)
AT (1) ATE266031T1 (de)
AU (1) AU2001292579A1 (de)
DE (1) DE60103171T2 (de)
DK (1) DK1325011T3 (de)
ES (1) ES2220811T3 (de)
PT (1) PT1325011E (de)
TR (1) TR200401316T4 (de)
WO (1) WO2002028861A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
EP2102207B1 (de) 2006-12-07 2010-06-02 F.Hoffmann-La Roche Ag Spiropiperidinderivate als antagonisten des via-rezeptors
WO2008077810A2 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
US20110224221A1 (en) * 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
CN103965204B (zh) * 2008-11-19 2016-09-07 赛福伦公司 吲唑并[5,4-a]吡咯并[3,4-c]咔唑化合物的新形式
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
NZ604135A (en) * 2010-05-18 2015-02-27 Cephalon Inc Method for purifying a fused pyrrolocarbazole derivative
EP3399026A1 (de) 2010-06-14 2018-11-07 The Scripps Research Institute Neuprogrammierung von zellen für ein neues zellschicksal
JP2013545758A (ja) 2010-11-17 2013-12-26 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護
US9487530B2 (en) 2013-03-15 2016-11-08 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
US20150297607A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
EP3606518A4 (de) 2017-04-01 2021-04-07 The Broad Institute, Inc. Verfahren und zusammensetzungen zur detektion und zur modulation einer immuntherapieresistenzgensignatur in krebs
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5679694A (en) * 1992-07-20 1997-10-21 The Wellcome Foundation Ltd. Tetracyclic compounds, intermediates for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
US7109229B2 (en) 2006-09-19
WO2002028861A2 (en) 2002-04-11
DE60103171D1 (de) 2004-06-09
AU2001292579A1 (en) 2002-04-15
TR200401316T4 (tr) 2004-07-21
ATE266031T1 (de) 2004-05-15
WO2002028861A8 (en) 2003-11-20
ES2220811T3 (es) 2004-12-16
PT1325011E (pt) 2004-09-30
US20040048915A1 (en) 2004-03-11
EP1325011B1 (de) 2004-05-06
DE60103171T2 (de) 2004-11-11
EP1325011A2 (de) 2003-07-09
WO2002028861A3 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
NO20061080L (no) Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler
NO20045043L (no) Pyrimidinonforbindelser, sammensetninger og fremgangsmater
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
NO20070782L (no) Tetrapeptidanaloger.
LU92338I2 (fr) Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
MXPA05013977A (es) Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
DK1305286T3 (da) Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
NO20073113L (no) Indenylderivater og anvendelse derav for behandling av neurologiske lidelser
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
TW200508233A (en) Chk-1 inhibitors
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
DE60106947D1 (de) Oxindolderivate
EA200700692A1 (ru) Пиридиновые производные индолин-2-она, их получение и их прменение в терапии